ALLMedicine™ Polycythemia Vera Center
Research & Reviews 1,220 results
https://doi.org/10.1093/labmed/lmac074
Laboratory Medicine; Puglianini OC, Peker D et. al.
Aug 13th, 2022 - Although several decades have passed since the description of myeloproliferative neoplasms (MPN), many aspects of their pathophysiology have not been elucidated. In this review, we discuss the mutational landscape of patients with essential thromb...
https://doi.org/10.1097/MD.0000000000030064
Medicine Li WW, Sui XF et. al.
Aug 13th, 2022 - Transformation from chronic myeloproliferative neoplasm to acute leukemia is a feature of myeloproliferative neoplasm; however, the rate is not high. Transformation to acute promyelocytic leukemia is rare. Here, we report a case of transformation ...
https://clinicaltrials.gov/ct2/show/NCT05452564
Aug 12th, 2022 - HIV infection is controllable with antiretroviral therapy (ART), but ART cannot eliminate HIV reservoirs. Thus, there is no available cure for HIV. There is a large and growing body of evidence that the central nervous system (CNS) is an HIV reser...
https://clinicaltrials.gov/ct2/show/NCT05499013
Aug 12th, 2022 - This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, phar...
https://clinicaltrials.gov/ct2/show/NCT03165734
Aug 11th, 2022 - The study is a randomized, controlled phase 3 study comparing the efficacy of pacritinib with P/C therapy in patients with PMF, PPV-MF, or PET-MF (Dynamic International Prognostic Scoring System [DIPSS] risk score of Intermediate-1 to High-Risk), ...
Guidelines 3 results
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.
Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...
https://doi.org/10.6004/jnccn.2016.0169
Journal of the National Comprehensive Cancer Network : JN... Mesa R, Jamieson C et. al.
Dec 14th, 2016 - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagn...
https://doi.org/10.1007/s00277-014-2224-8
Annals of Hematology; Kreher S, Ochsenreither S et. al.
Oct 14th, 2014 - Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) like polycythemia vera and essential thrombocythemia are at increased risk of arterial and venous thrombosis. Strategies of prevention may consist of platelet aggreg...
Drugs 13 results see all →
Clinicaltrials.gov 132 results
https://clinicaltrials.gov/ct2/show/NCT05452564
Aug 12th, 2022 - HIV infection is controllable with antiretroviral therapy (ART), but ART cannot eliminate HIV reservoirs. Thus, there is no available cure for HIV. There is a large and growing body of evidence that the central nervous system (CNS) is an HIV reser...
https://clinicaltrials.gov/ct2/show/NCT05499013
Aug 12th, 2022 - This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, phar...
https://clinicaltrials.gov/ct2/show/NCT03165734
Aug 11th, 2022 - The study is a randomized, controlled phase 3 study comparing the efficacy of pacritinib with P/C therapy in patients with PMF, PPV-MF, or PET-MF (Dynamic International Prognostic Scoring System [DIPSS] risk score of Intermediate-1 to High-Risk), ...
https://clinicaltrials.gov/ct2/show/NCT04676529
Aug 10th, 2022 - The study consists of two phases: a dose escalation phase and a cohort expansion phase. The dose escalation phase will follow a 3+3 design with a starting dose of 100 mg twice daily, and a treatment duration of 4 weeks. Patients will be able to pa...
https://clinicaltrials.gov/ct2/show/NCT03755518
Aug 9th, 2022 - This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV M...
News 240 results
https://www.medscape.com/viewarticle/972789
Apr 27th, 2022 - In 2021, the Food and Drug Administration approved 50 new drugs, but 24 will not be described here because they would probably not be used in pregnancy. The 24 are Aduhelm (aducanumab) to treat Alzheimer’s disease; Azstarys (serdexmethylphenidate ...
https://www.mdedge.com/obgyn/article/254158/obstetrics/review-new-drugs-may-be-used-during-pregnancy
Gerald G. Briggs, BPharm, FCCP
Apr 26th, 2022 - In 2021, the Food and Drug Administration approved 50 new drugs, but 24 will not be described here because they would probably not be used in pregnancy. The 24 are Aduhelm (aducanumab) to treat Alzheimer’s disease; Azstarys (serdexmethylphenidate.
https://www.onclive.com/view/pacritinib-paves-a-unique-lane-of-treatment-for-select-myelofibrosis
Apr 5th, 2022 - Patients who develop post–essential thrombocythemia myelofibrosis (PET-MF) or post–polycythemia vera myelofibrosis (PPV-MF), which are associated with significant symptom burden and bone marrow failure, have limited therapies available for effecti...
https://www.onclive.com/view/nccn-recommends-ropeginterferon-alfa-2b-in-clinical-practice-guidelines-update
Mar 24th, 2022 - The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology has been revised to include ropeginterferon alfa-2b-njft (Besremi) as a recommended treatment option for adult patients with polycythemia vera, according to ...
https://www.mdedge.com/fedprac/article/252920/neurology/clinical-presentation-subacute-combined-degeneration-patient
Nathan Kostick, Evan Chen et. al.
Mar 21st, 2022 - Subacute combined degeneration (SCD) is an acquired neurologic complication of vitamin B12 (cobalamin) or, rarely, vitamin B9 (folate) deficiency. SCD is characterized by progressive demyelination of the dorsal and lateral spinal cord, resulting i.